David Roth insider trades: Syros Pharmaceuticals (SYRS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | SYRS | ↓ Sell | 12,099 | $0.20 | $2K | Direct | Nov 20, 2024 (2d) |
| Apr 3, 2024 | SYRS | ↓ Sell | 10,451 | $4.95 | $52K | Direct | Apr 5, 2024 (2d) |
| Apr 2, 2024 | SYRS | ↓ Sell | 150 | $4.98 | $747 | Direct | Apr 2, 2024 (0d) |
| Dec 12, 2023 | SYRS | ↓ Sell | 6,287 | $4.95 | $31K | Direct | Dec 14, 2023 (2d) |
| Dec 6, 2023 | SYRS | ↓ Sell | 6,287 | $3.95 | $25K | Direct | Dec 8, 2023 (2d) |
| Jul 31, 2023 | SYRS | ↓ Sell | 7,348 | $3.95 | $29K | Direct | Aug 2, 2023 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About David Roth's insider trades
David Roth is Chief Medical Officer at Syros Pharmaceuticals (SYRS). Since Jul 31, 2023, David has reported no open-market purchases and 6 sales worth $140K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), shares withheld for taxes (5 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SYRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.